Drugs / 2-Deoxy-D-ribose
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07502976 | Jan → Oct 2026 expected | androgenetic alopecia | Kasr El Aini Hospital | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 2-Deoxy-D-ribose | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07502976 ↗ |
| Known as | 2dDR | “topical 2-Deoxy-D-ribose (2dDR) hydrogel compared with topical minoxidil 5% solution” NCT07502976 ↗ |
| Action | Activate | “2dDR), a deoxypentose sugar with pro-angiogenic properties, may stimulate angiogenesis through upregulation of VEGF” NCT07502976 ↗ |
| Modality | Small molecule | “2-Deoxy-D-ribose (2dDR), a deoxypentose sugar with pro-angiogenic properties” NCT07502976 ↗ |
| Route | Topical | “Topical 2-Deoxy-D-ribose hydrogel prepared with sodium alginate. The hydrogel will be composed of sodium alginate, propylene glycol, 2-phenoxyethanol, and 2-Deoxy-D-ribose in...” NCT07502976 ↗ |